Medivir appoints vp for r&d projects

Charlotte Edenius takes up newly created position

Medivir, a Swedish research-based specialist pharmaceutical company focused on infectious diseases, has appointed Charlotte Edenius to the new position of vice president, research & development projects.

Edenius holds a medical degree and has a PhD from the Karolinska Institute. She joined Medivir this month from Swedish pharmaceutical company Orexo, where she was senior vice president and chief scientific officer.

Prior to this, Edenius was vice president and chief scientific officer of Biolipox from 2001–2007 and held various executive positions in experimental medicine, Clinical R&D at AstraZeneca in Sweden.

Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

You may also like

Research & Development

Medivir partners with GVK BIO to optimise R&D

Company reorganises its discovery and research operations and focuses on key areas of oncology and infectious diseases
Research & Development

Medivir and Cancer Research Technology link up to develop new cancer drugs

Will conduct a two-year research programme to develop small molecules targeting the ADAM8 protein
Research & Development

Medivir to develop new drugs for bacterial infections

Swedish University of Agricultural Sciences will receive a fee for research services
Research & Development

Medivir signs dengue virus deal with Janssen

Strengthens presence in infectious diseases
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
Subscribe now